Demonstration of outcomes experienced by LIFEspan clients will quantify the value of a coordinated transfer approach and provide data for future studies examining the long-term implications of such a model on continuity of care, quality of life, inclusion, and participation.
Information about the value of ovarian suppression continues to emerge, most recently with the demonstration of excellent outcome with goserelin plus tamoxifen in the ABCSG12 trial.
The demonstration of poorer outcomes in patients exposed to inotropes is consistent with the results demonstrated in several previous studies.
Implementation of the ELPQuiC bundle and demonstration of improved outcomes in four different hospitals, all with their own unique contexts, provides evidence of external validity of the use of this approach to reduce mortality after emergency laparotomy.
For example, the demonstration of improved outcomes in patients with head and neck cancers when EGFR targeting is combined with radiation will naturally lead to new EGFR-targeted therapies being assessed with radiation in head and neck cancer cell lines.
In addition, we assessed the representativeness of the exposed cohort in the study setting; the selection of non-exposed cohorts; the ascertainment of exposure; the demonstration that outcome of interest was not present at start of study; the comparability of cohorts on the basis of design and analyses; the outcomes assessments; and the adequacy of follow-up (17).
However, the overall lack of a congruence effect does not bear on our robust demonstration of deficiencies in outcome knowledge in patients with OCD.
REC: representativeness of the exposed cohort; SNEC: selection of the non-exposed cohort; AE: ascertainment of exposure; DO: demonstration that outcome of interest was not present at start of study; SC: study controls for age, sex; AF: study controls for any additional factors; AO: assessment of outcome; FU: follow-up long enough for outcomes to occur; FUO: adequacy of follow-up of cohorts.
For this review, four of the nine items were relevant ("representativeness of the exposed cohort", "demonstration that outcome of interest not present at start of study", "assessment of outcome" and "adequacy of follow-up").
The first relates to the possibility that there may be a lag in the effect of AED treatment on PRO outcomes after demonstration of positive treatment effect on clinical efficacy outcomes e.g. seizure frequency/occurrence. Qualitative studies show that unpredictability of seizures is a key factor in the impact of epilepsy for patients [ 19- 21].
